Modality
Peptide
MOA
TYK2i
Target
RET
Pathway
Tau
AsthmaMDDSCD
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
~Mar 2018
→ ~Jun 2019
Phase 2
Sep 2019
→ Jul 2027
Phase 2Current
NCT04962915
1,870 pts·MDD
2019-09→2027-07·Not yet recruiting
1,870 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-241.3y awayPh3 Readout· MDD
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Not yet…
Catalysts
Ph3 Readout
2027-07-24 · 1.3y away
MDD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04962915 | Phase 2/3 | MDD | Not yet recr... | 1870 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |